BioAtla, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | — | $300,000 |
| Research and development | $43.6M | $63.1M | $103.7M | $79.3M | $58.3M |
| Operating expenses | $61.3M | $84.9M | $129.7M | $108.1M | $96.7M |
| Operating income | -$59.3M | -$73.9M | -$129.7M | -$108.1M | -$96.4M |
| Interest expense | — | — | — | $0 | $3,000 |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$59.6M | -$69.8M | -$123.5M | -$106.5M | -$95.4M |
| Balance Sheet | |||||
| Cash and equivalents | $7.1M | $49.0M | $111.5M | $215.5M | $245.0M |
| Current assets | $8.0M | $51.2M | $116.4M | $220.4M | $247.3M |
| Total assets | $13.8M | $52.4M | $119.7M | $225.7M | $254.4M |
| Current liabilities | $21.9M | $14.5M | $28.3M | $23.1M | $19.8M |
| Total liabilities | $50.0M | $38.2M | $49.0M | $45.4M | $43.6M |
| Stockholders' equity | -$36.2M | $14.3M | $70.7M | $180.3M | $210.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$48.2M | -$71.9M | -$104.0M | -$90.4M | -$62.2M |
| Depreciation and amortization | $373,000 | $925,000 | $1.2M | $1.2M | $1.3M |
| Stock-based compensation | $5.4M | $8.9M | $13.5M | $14.6M | $25.1M |
| Capital expenditure | — | — | $0 | $1,000 | $1,000 |
| Free cash flow | — | — | -$104.0M | -$90.4M | -$62.2M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 1.7M · Free float 90.6%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.